Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia.
Aged
Antiplatelet
Aspirin
COVID-19
Coronavirus
Mortality
Pneumonia
Journal
GeroScience
ISSN: 2509-2723
Titre abrégé: Geroscience
Pays: Switzerland
ID NLM: 101686284
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
21
09
2021
accepted:
13
12
2021
pubmed:
8
1
2022
medline:
31
5
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
Platelet aggregation has been associated with COVID-19 pathogenesis. In older patients hospitalized for SARS-CoV-2 pneumonia, we aimed to investigate the association between aspirin use before admission and the risk of in-hospital all-cause mortality. We performed a retrospective international cohort study in five COVID-19 geriatric units in France and Switzerland. Among 1,357 consecutive hospitalized patients aged 75 or older and testing positive for SARS-CoV-2, we included 1,072 with radiologically confirmed pneumonia. To adjust for confounders, a propensity score for treatment was created, and stabilized inverse probability of treatment weighting (SIPTW) was applied. To assess the association between aspirin use and in-hospital 30-day mortality, SIPTW-adjusted Kaplan-Meier and Cox proportional hazards regression analyses were performed. Of the 1047 patients with SARS-CoV-2 pneumonia and median age 86 years, 301 (28.7%) were taking aspirin treatment before admission. One hundred forty-seven (34.3%) patients who had taken aspirin died in hospital within 1 month vs 118 patients (30.7%) without aspirin. After SIPTW, aspirin treatment was not significantly associated with lower mortality (adjusted hazard ratio: 1.10 [0.81-1.49], P = .52). Moreover, patients on aspirin had a longer hospital stay and were more frequently transferred to the intensive care unit. In a large multicenter cohort of older inpatients with SARS-CoV-2 pneumonia, aspirin use before admission did not appear to be associated with an improved prognosis.
Identifiants
pubmed: 34993763
doi: 10.1007/s11357-021-00499-8
pii: 10.1007/s11357-021-00499-8
pmc: PMC8736303
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-583Informations de copyright
© 2022. The Author(s), under exclusive licence to American Aging Association.
Références
Panka BA, de Grooth H-J, Spoelstra–de Man A, Looney M, Tuinman P-R. Prevention or treatment of ARDS with aspirin: a review of preclinical models and meta- analysis of clinical studies. Shock. 2017;47:13–21.
doi: 10.1097/SHK.0000000000000745
Gallay L, Tran V-T, Perrodeau E, Vignier N, Mahevas M, Bisio F, et al. Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study. Clin Microbiol Infect. 2021;27:1145–50.
doi: 10.1016/j.cmi.2021.03.021
Bianconi V, Violi F, Fallarino F, Pignatelli P, Sahebkar A, Pirro M. Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19 ? Drugs. 2020;80:1383–96.
doi: 10.1007/s40265-020-01365-1
Gurbel PA, Bliden KP, Schrör K. Can an old ally defeat a new enemy? Circulation. 2020;142:315–7.
doi: 10.1161/CIRCULATIONAHA.120.047830
Falcone M, Russo A, Cangemi R, Farcomeni A, Calvieri C, Barillà F, et al. Lower mortality rate in elderly patients with community‐onset pneumonia on treatment with aspirin. J Am Heart Assoc. 2015;4.
Hamilton F, Arnold D, Henley W, Payne RA. Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. Eur Respir J. 2020;57:2002795.
Srivastava R, Kumar A. Use of aspirin in reduction of mortality of COVID-19 patients: a metanalysis. Int J Clin Pract. 2021;75:e14515.
Salah HM, Mehta JL. Meta-analysis of the effect of aspirin on mortality in COVID-19. Am J Cardiol. 2021;142:158–9.
doi: 10.1016/j.amjcard.2020.12.073
Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. 2021;96:471–9.
doi: 10.1002/ajh.26102
Liu Q, Huang N, Li A, Zhou Y, Liang L, Song X, et al. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19. Medicine. 2021;100:e24544.
doi: 10.1097/MD.0000000000024544
Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, et al. Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19. Anesthesia & Analgesia. 2020;Publish Ahead of Print.
Savarapu P, Baral N, Adhikari G, Akanbi M, Abdelazeem B, Isa SO, et al. Aspirin use is associated with decreased mortality in patients with COVID-19: a systematic review and meta-analysis. preprint. Infectious Diseases (except HIV/AIDS); 2021.
Haji Aghajani M, Moradi O, Amini H, Azhdari Tehrani H, Pourheidar E, Rabiei MM, et al. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19. J Med Virol. 2021;93:5390–5.
doi: 10.1002/jmv.27053
RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Staplin N, Emberson JR, Campbell M, et al. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. preprint. Infectious Diseases (except HIV/AIDS); 2021.
Xu Q, Samanapally H, Nathala P, Salunkhe V, Furmanek S, Cahill MN, et al. Outcomes and risk factors for cardiovascular events in hospitalized COVID-19 patients. J Cardiothorac Vasc Anesth. 2021. https://doi.org/10.1053/j.jvca.2021.03.035 .
doi: 10.1053/j.jvca.2021.03.035
pubmed: 34753654
pmcid: 7997853
Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76:533–46.
doi: 10.1016/j.jacc.2020.06.007
Xu H, Hou K, Xu R, Li Z, Fu H, Wen L, et al. Clinical characteristics and risk factors of cardiac involvement in COVID-19. J Am Heart Assoc. 2020;9:e016807.
doi: 10.1161/JAHA.120.016807
Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Röösli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans health administration. PLOS ONE. 2021;16:e0246825.
doi: 10.1371/journal.pone.0246825
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45-67.
doi: 10.1164/rccm.201908-1581ST
Odille G, Girard N, Sanchez S, Lelarge S, Mignot A, Putot S, et al. Should we prescribe antibiotics in older patients presenting COVID-19 pneumonia? J Am Med Dir Assoc. 2021;22:258–9.
Mendes A, Serratrice C, Herrmann FR, Genton L, Périvier S, Scheffler M, et al. Predictors of in-hospital mortality in older patients with COVID-19: the COVID age study. J Am Med Dir Assoc. 2020;21:1546-1554.e3.
doi: 10.1016/j.jamda.2020.09.014
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.
doi: 10.1001/jama.1963.03060120024016
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.
doi: 10.1136/thorax.58.5.377
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.
doi: 10.1056/NEJM199701233360402
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61-111.
doi: 10.1093/cid/ciw353
Granger E, Sergeant JC, Lunt M. Avoiding pitfalls when combining multiple imputation and propensity scores. Stat Med. 2019;38:5120–32.
doi: 10.1002/sim.8355
Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13:273–7.
doi: 10.1111/j.1524-4733.2009.00671.x
Linden A, Samuels SJ. Using balance statistics to determine the optimal number of controls in matching studies. J Eval Clin Pract. 2013;19:968–75.
doi: 10.1111/jep.12072
Alves M, Fernandes MA, Bahat G, Benetos A, Clemente H, Grodzicki T, et al. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications. Eur Geriatr Med. 2021;12:725–39.
doi: 10.1007/s41999-021-00504-5
Rizk JG, Lavie CJ, Gupta A. Low-dose aspirin for early COVID-19: does the early bird catch the worm? Expert Opin Investig Drugs. 2021;30:785–8.
Eisen DP, Leder K, Woods RL, Lockery JE, McGuinness SL, Wolfe R, et al. Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial. Lancet Respir Med. 2021;9:186–5.
Son M, Noh M-G, Lee JH, Seo J, Park H, Yang S. Effect of aspirin on coronavirus disease 2019: a nationwide case-control study in South Korea. Med (Baltimore). 2021;100:e26670.
doi: 10.1097/MD.0000000000026670
Keane C, Tilley D, Cunningham A, Smolenski A, Kadioglu A, Cox D, et al. Invasive Streptococcus pneumoniae trigger platelet activation via Toll-like receptor 2. J Thromb Haemost. 2010;8:2757–65.
doi: 10.1111/j.1538-7836.2010.04093.x
Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020;13:120.
doi: 10.1186/s13045-020-00954-7
Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang C-CH, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313:264–74.
doi: 10.1001/jama.2014.18229
Putot A, Chague F, Manckoundia P, Cottin Y, Zeller M. Post-infectious myocardial infarction: new insights for improved screening. JCM. 2019;8:827.
doi: 10.3390/jcm8060827
Oz F, Gul S, Kaya MG, Yazici M, Bulut I, Elitok A, et al. Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. Coron Artery Dis. 2013;24:231–7.
doi: 10.1097/MCA.0b013e32835d7610
Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol. 2014;64:1917–25.
doi: 10.1016/j.jacc.2014.07.985